益气复脉注射液治疗慢性心力衰竭的系统评价再评价

Yiqi Fumai injection in the treatment of chronic heart failure:an overview of systematic reviews

目的对益气复脉注射液治疗慢性心力衰竭的系统评价进行再评价。方法计算机检索PubMed、Cochrane Library、EMbase、Web of Science、CNKI、CBM和WanFang Data数据库,搜集益气复脉注射液治疗慢性心力衰竭的系统评价,检索时限均为2007年1月1日至2022年10月31日。由2名研究者独立筛选文献、提取资料后,分别采用AMSTAR-2、ROBIS量表、PRISMA及GRADE系统评价其方法学质量、偏倚风险、报告质量和证据质量。结果共纳入7个系统评价。评价结果显示,纳入系统评价的方法学质量都较低,少数系统评价为低偏倚风险,纳入系统评价报告较完整。从纳入系统评价中提取46个结果进行评价,有3个为中级质量证据,12个为低级质量证据,31个为极低级质量证据。结论益气复脉注射液可能是一种有效且安全的治疗方法,但当前证据质量较低。

Objective To overview of systematic reviews(SRs)of Yiqi Fumai(YQFM)injection in the treatment of chronic heart failure(CHF).Methods The PubMed,Cochrane Library,EMbase,Web of Science,CNKI,CBM and WanFang Data databases were electronically searched to collect SRs of YQFM injection in the treatment of CHF from January 1,2007 to October 31,2022.Two reviewers independently screened literature,extracted data and assessed methodological quality,risk of bias,report quality and evidence quality by using AMSTAR-2,ROBIS scale,PRISMA,and GRADE system.Results A total of 7 SRs were included.The evaluation results showed that the quality of all SRs was low,a few SRs were assessed as having a low risk of bias,and all SRs were relatively completely reported.A total of 46 results were extracted from the included SRs,including 3 with moderate quality evidence,12 with low quality evidence and 31 with very low quality evidence.Conclusion YQFM may be an effective and safe treatment,but current evidence quality is low.